Intralesional penicillamine in the treatment of keloids and hypertrophic scars

Open labeled therapeutic trial

https://doi.org/10.53730/ijhs.v6nS5.10553

Authors

  • Jamal R. Al-Rawi MBChB, MSc, FICMS
  • Mohammed J. E. Ahmed MBChB, CABMS
  • Ali K. Taher MBChB

Keywords:

Intralesional penicillamine, Keloid, Hypertrophic scars

Abstract

Background: Many therapeutic options have been tried in the treatment of keloid and hypertrophic scars, but no one is superior to others. Penicillamine has been used systemically but not tested as intralesional. Objective: The aim of this study was to evaluate the effectiveness & safety of intralesional penicillamine for treatment of keloids and hypertrophic scars. Patients and Method:  this is open labeled therapeutic trial study encountered in Department of Dermatology and Venereology in Al-Yarmouk teaching Hospital, Baghdad-Iraq. Collection of data was carried out during the period between May 2010 – February 2011. This study included 28 patients with keloids and hypertrophic scars.  Penicillamine was prepared as a solution for intralesional injection by dissolving (250mg) of Penicillamine (Artamin)® by SANDOZ in (10ml) distilled water in sterilized container to obtained (2.5%) concentration of Penicillamine and autoclaved at 121C0 for 20 min before use. Penicillamine was administered with 27-gauge needle syringe without anesthesia. Seventy percent ethanol was used as an antiseptic agent before injection. Four sessions of intralesional injection were given at intervals of 15 days each.

Downloads

Download data is not yet available.

References

Berman B, Flores F. Comparison of a silicone gel-filled cushion and silicone gel sheeting for the treatment of hypertrophic or keloid scars. Dermatol Surg. Jun 1999; 25(6):484-6.

I.T. Jackson, R. Bhageshpur, V. DiNick, A. Khan and S. Bhaloo. Investigation of recurrence rates among earlobe keloids utilizing various postoperative therapeutic modalities. Eur J Plast Surg. 2001;24(2):88–95.

Alhady SM, Sivanantharajah K. Keloids in various races. A review of 175 cases. Plast Reconstr Surg. Dec 1969; 44(6):564-6.

Bradon J Wilhelmi, MD, Professor and Endowed Leonard J Weiner, MD, Chair of Plastic Surgery, Residency Program Director, University of Louisville School of Medicine Updated: Dec 17, 2008.

Marneros AG, Norris JE, Watanabe S, Reichenberger E, Olsen BR. Genome scans provide evidence for keloid susceptibility loci chromosomes 2q23 and 7p11. J Invest Dermatol. May 2004; 122(5):1126-32.

Crikelair GF, Ju DM, Cosman B. Scars and keloids. In: Converse JM, ed. Reconstructive Plastic Surgery: Principles & Procedures in Correction Reconstruction & Transplantation. 2nd ed. Philadelphia, Pa: WB Saunders; 1977; 413.

Cohen IK, McCoy BJ, Mohanakumar T, Diegelmann RF. Immunoglobulin, complement, and histocompatibility antigen studies in keloid patients. Plast Reconstr Surg. May 1979; 63(5):689-95.

Castagnoli C, Stella M, Berthod C., Magliacani G, Richiardi PM. TNF production and hypertrophic scarring. Cell Immunol. Mar 1993; 147(1):51-63.

Lee JY, Yang CC, Chao SC. Histopathological differential diagnosis of keloid and hypertrophic scar. Am J Dermatopathol. Oct 2004; 26(5):379-84.

Niessen FB, Spaumen PH, Schalkwij KJ. On the nature of hypertrophic scars and keloids: a review Plast Recon Surg 1999; 104: 1435-58.

From L, Assaad D. Neoplasms, pseudoneoplasms and hyper plasias of the dermis. In Freedberg IM, Eisen AZ, Wolff K. eds. Dermatology in General Medicine. New York: McGraw-Hill; 1999. p. 1161-75.

Berman B, Valins W, Amini S, Viera MH. Keloid and hypertrophic scar. eMedicine from WebMD. Updated: May 14, 2010 Available at: http://emedicine.medscape.com/article.

Kaushik, Basant, Verma Laxmi, Patel Roshan, Gendle Ravindra, and Verma Shekhar, Keloid and hypertrophic scars: A review in Pharmaceutical Reviews. Vol. 6 Issue 5, 2008.

Ellitsgaard V, Ellitesgaard N, hypertrophic scars and keloids: a recurrent problem revisited, Acta Chir Plast, 1997; 39(3): 69-77.

Walshe JM (January 1956). "Wilson's disease; new oral therapy". Lancet 267 (6906): 25–6.

Drug Information for the Health Care Professional (USP DI) R, Vol. I, 16th ed., 1996, p. 2297.

Louise Cope Moorhead Current Eye Research Jan 1981, Vol. 1, No. 2, Pages 77-84: 77-84 Inhibition of collagen cross-linking: A new approach to ocular scarring.

Dr Marcel E Nimni (Departments of Biochemistry and Medicine,Univetsity of Southern California, School of Medicine, Los Angeles, California, 90033) Introduction .... 68 Proc. roy. Soc.Med.Volume70,1977,Supplement3.www.ncbi.nlm.nih.gov/pmc/articles/.../pdf/procrsmed00107-0072.pdf.

Hom DB. A new era of discovery in facial plastic surgery. Arch Facial Plast Surg.2000; 2:166-172.

R Edward Newsome, MD, Program Director and Chief of Plastic Surgery, Henderson Chair in Surgery, Assistant Dean for Graduate Medical Education, Tulane University School of Medicine Updated: Jun 26, 2009 Available at: http://emedicine.medscape.com/article.

A. PAULKELLY Division of Dermatology, King/Drew Medical Center, Los Angeles, CA Medical and surgical therapies for keloids Dermatologic Therapy, Vol. 17, 2004, 212–218.

BRYAN J. MAYOU. D-Penicillamine in the treatment of keloids.Department of Plastic Surgery, St Thomas's Hospital, London SE, British Journal of Dermatology (1981) 105, 87.

Cosman B,CrikelairGF,JuDMC,Gaulin JC,LattesR,The surgical treatment of keloids.Plast Reconstr Surg. 1961;27:335-56.

Ramakrishnan KM,Thomas KP,Sundararajan CR.Study of 1,000 patients with keloids in South India. Plast Reconstr Surg.1974; 53:276-80.

Rockwell WB, Cohen IK, Ehrlich HP. Keloids and hypertrophic scars: a comprehensive review. Plast Reconstr Surg. Nov 1989; 84(5):827-37.

Bayat A, Arscott G, Ollier WE, McGrouther DA, Ferguson MW. Keloid disease: clinical relevance of single versus multiple site scarsBr J Plast Surg. 2005 Jan;58(1):28-37.

English SE, Shenefelt PD. Keloid and hypertrophic scars. Dermatol Surg. 1999; 25:631-38.

Fatemi Naecini Farahnaz, Najafian Jamshid, Ahmadpour Koroush. Comparison of therapeutic response of keloids and hypertrophic scars to cryotherapy plus intralesional steroid and bleomycin: 2005; 50(3): 129-32.

Fitzpatrick RE. Treatment of hypertrophic scars using intralesional 5-FU. Dermatol Surg 1999; 25:224-32.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864

Espana A, Solano T, Quintanilla E. Bleomycin in the treatment of keloids and hypertrophic scars. Dermatol Surg 2001; 27:23-7.

Darzi MA, Choudii NA, Kaul SK. Evaluation of various methods of treating keloids and hypertrophic scars: a 10-year follow-up study. Br J Plast Surg 1992; 45: 374.

Al-Attar A, Mess S, Thomassen JM.: Keloid pathogenesis and treatment. Plast Reconstr Surg 2006; 117:286-300.

Norbert Kang, Branavan Sivakumar, Roy Sanders, Charles Nduka, David Gault. Intra-lesional injections of collagenase are ineffective in the treatment of keloid and hypertrophic scars, Journal of Plastic, Reconstructive& Aesthetic Surgery, 2006 February; 59(7): 693-99.

Published

10-07-2022

How to Cite

Al-Rawi, J. R., Ahmed, M. J. E., & Taher, A. K. (2022). Intralesional penicillamine in the treatment of keloids and hypertrophic scars: Open labeled therapeutic trial. International Journal of Health Sciences, 6(S5), 2722–2734. https://doi.org/10.53730/ijhs.v6nS5.10553

Issue

Section

Peer Review Articles

Most read articles by the same author(s)